An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is effective to give HIV positive patients
recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy. Patients will be followed
over a minimum of 4 years to study the long-term effects of rIL-2 on their HIV disease
progression.
Anti-HIV therapy has been very successful in treating HIV positive patients and in keeping
viral load (level of HIV in the blood) low. However, anti-HIV drugs cannot completely rid the
body of the virus, and the immune system is never completely restored in HIV positive
patients. Doctors hope that giving patients recombinant interleukin-2 (rIL-2) in addition to
their anti-HIV therapy will help improve their immune systems and keep them healthier over a
longer period of time. rIL-2 is a hormone naturally produced by the body during an immune
response to a microbial infection.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)